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Abstract.  Permeabilized nuclei from mammalian cells 
encapsulated within agarose microbeads in an isotonic 
buffer are active in transcription and replication (Jack- 
son, D. A., and P.  R. Cook.  1985. EMBO (Eur. Mol. 
Biol.  Organ.) J.  4:913-918).  Their DNA is intact and 
the nuclei are accessible to macromolecules. Myeloma 
nuclei prepared in this way were used to probe the ex- 
tent of DNA negative supercoiling and the effects of 
altering torsional strain by binding radioactively la- 
beled monoclonal antibodies to Z-DNA. Control ex- 
periments used monoclonal antibodies against a non- 
histone chromosomal protein, HMG-17. On increasing 
the amount of anti-HMG-17 added, a binding plateau 
was reached encompassing a 200-fold range of anti- 
body concentration. On binding anti-Z-DNA antibody, 
a similar broad plateau of constant binding was found 
encompassing a  100-fold range of antibody concentra- 
tion. The latter result was taken as a measure of 
preexisting Z-DNA in the nuclei. Additional anti-Z- 
DNA antibody binding can be "induced" in the pres- 
ence of much higher concentration of antibody, appar- 
ently by perturbing the B-DNA/Z-DNA equilibrium. 
On inhibiting topoisomerase I with camptothecin, an 
elevated antibody binding plateau was found, suggest- 
ing that elastic torsional strain in the DNA is responsi- 
ble for stabilizing the preexisting Z-DNA. This in- 
terpretation is supported by the fact that addition of 
small, nicking amounts of DNase I leads to a com- 
plete loss of antibody binding in the Z-DNA plateau 
region but not in the region of "induced" Z-DNA. 
NA can assume both right-handed and left-handed con- 
formations.  The left-handed Z-DNA  conformation 
is in equilibrium with the right-handed conformation 
but under physiological solvent conditions it is at a higher 
energy state (see references 14 and 24 for reviews). Z-DNA 
can be stabilized in vivo either by negative supercoiling (13, 
23, 26) or by Z-DNA binding proteins (1,  17). An unsolved 
problem  is the extent to which  DNA  is negatively super- 
coiled in vivo, and the extent to which the Z-DNA conforma- 
tion exists within the nucleus under physiologically relevant 
conditions.  Several  studies  addressing  this  problem  have 
been carried out using antibodies to Z-DNA and cells fixed 
for morphological investigation (15, 20, 22). However, chro- 
matin in these studies was far from a physiological environ- 
ment.  Fixing cells generally  involves the addition  of sub- 
stances  such as acetic  acid or ethanol  that remove DNA 
bound proteins from the nucleus (4, 28). DNA in the nucleus 
is wound around proteins and removal of even a portion of 
those  proteins  releases  negatively  supereoiled,  elastically 
strained DNA which may adopt the Z conformation.  Like- 
wise,  microdissecting  a Drosophila  polytene chromosome 
and placing it in a buffer solution for staining with antibodies 
is far from the physiological environment of the intact nu- 
cleus (8). 
We have addressed this problem using the novel  technique 
developed by Jackson  and Cook (3,  9-12).  In this proce- 
dure,  living cells  are encapsulated  within  agarose  micro- 
beads which have large pores allowing free movement  of  mac- 
romolecules into and out of  the beads (3, 10). When the cells 
are treated with a detergent (0.5% Triton X-100) in an iso- 
tonic salt solution,  the plasma membrane  and the soluble 
contents of cytoplasm are removed but the nucleus remains 
morphologically intact, and permeable to macromolecules. 
The DNA in the agarose embedded nucleus is unbroken and 
the nucleus remains active in both transcription and replica- 
tion (9, 11, 12). Jackson and Cook have found that the intact 
chromatin template replicates DNA at 85 % of  the rate found 
in vivo (12). This represents a useful preparation for probing 
the torsional state of the DNA.  Will antibodies to Z-DNA 
bind to these unfixed, metabolically active nuclei? 
In the present work, we have used monoclonal antibodies 
that have been shown to bind to Z-DNA independent of its 
nucleotide sequence (19, 21, 25; reviewed in reference 27). 
The antibodies have been biotinylated. Subsequently, either 
radioactive  or fluorescently  labeled  streptavidin has  been 
added.  Control experiments have used a monoclonal anti- 
body against the nonhistone chromosomal protein HMG-17. 
On adding increasing amounts of anti-HMG-17, an anti- 
body concentration-independent  binding plateau is found. 
At that plateau, there is approximately one antibody combin- 
ing  site  per  HMG-17 molecule.  Anti-Z-DNA  antibodies 
have been shown to "induce" Z-DNA formation by shifting 
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tions (16, 17). On raising the amount of anti-Z-DNA anti- 
body added, a binding plateau was found here as well, and 
the amount of binding remained constant over a 100-fold in- 
crease of antibody concentration. This was taken as a mea- 
sure of preexisting Z-DNA. However,  at even higher anti- 
body concentrations, the binding was observed to increase. 
We call this "inducible" Z-DNA. 
It is likely that the plateau binding level  of preexisting 
Z-DNA is maintained by torsional strain since addition of a 
topoisomerase I inhibitor results in an elevated level of the 
binding plateau. This interpretation is further supported by 
experiments  with  DNase  I.  Addition  of small  (nicking) 
amounts of DNase I results in the loss of all antibody binding 
in the preexisting Z-DNA binding plateau. However, it does 
not greatly affect the Z-DNA induced by much higher anti- 
body concentrations. 
Materials and Methods 
Encapsulation of Cells 
Mouse myeloma cells (X63-AG 8.6.5.3) were used in all of the experiments. 
The methods of cell preparation are adaptations of procedures published by 
Jackson and Cook (3, 9-12). Cells were grown in DME medium contain- 
ing 10% FCS supplemented with L-glutamine (2 raM), pyruvate (1 mM), 
glucose (3.5 g/liter), and penicillin-streptomycin solution (100 U/n'd). 5  × 
10  ~ cells were washed twice at room temperature with 50 mi each of PBS 
(150 mM NaC1, 8.4 mM Na2PO4,  1.5 mM KH2PO4, pH 7.2),  suspended 
with 20 ml of PBS to yield 2.5  ×  107 cells/nil, and kept at 39°C.  In sep- 
arate flasks,  5  ml of 2.5%  (wt/wt)  low melting agarose (type VII,  No. 
A-4018; Sigma Chemical Co.,  St. Louis,  MO) were liquified and subse- 
quently cooled to 39"C,  and 50  ml of liquid paraffin (model No.  7174; 
Merck, Bracco S. P. A., Milan) were warmed to 39°C. These three compo- 
nents were pooled in a 300-ml Erlenmeyer flask, prewarmed to 39°C,  in 
the order paraffin-cells-agarose, emulsified by shaking at 400 rpm in a ro- 
tary shaker (model G-76; New Brunswick Scientific Co., Inc., Edison, NJ) 
at 20°C for 30 s, and equilibrated in an ice-water bath to 0°C for 5 min. 
Then 100 ml of ice-cold PBS were added and immediately mixed by manu- 
ally rotating the flask. After quickly distributing the solution into glass cen- 
trifuge tubes (80 nd), the emulsion was centrifuged at 3,500 g and 0°C for 
5 min. The supernatant phase was totally removed by aspiration. The mi- 
crobead pellet was washed three times with 60 ml of ice-cold PBS for each 
tube, centrifuging at 4,800 g. The pellets were united resulting in 10-12 ml 
of microbead encapsulated living cells. Cell lysis and permeabilization of 
nuclei:  Microbeads were suspended in 3  vol of ice-cold cell lysis buffer 
(0.5%  [wt/vol] Triton X-100,  100 mM KCI,  25  mM  Naz EDTA,  1 mM 
fliT,  10 mM Tris-HC1, pH 7.6) and kept in an ice-water bath with gentle 
stirring for 20 rain.  After centfifugational sedimentation (4,800 g,  0°C, 
5 rain) and washing three times each with 5 vol (relative to the original pellet 
volume) of isotonic buffer (100 mM KCI, 25 mM [NI-I412SO4, 1 mM EDTA, 
1 mM DTT, 0.2% [wt/vol] BSA, 5% [vol/vol] glycerol, 20 mM Tris-HCl, 
pH 7.6),  the microbeads were suspended with an equal volume of isotonic 
buffer. 
Fluorescence Microscopy 
For fluorescence microscopic studies, FITC-labeled streptavidin was used. 
In the case of the FITC label, to each 500/zl aliquot, 5 ttl of FITC-strep- 
tavidin (RPN.1232;  Amersham Corp., Arlington Heights, IL) was added. 
The suspension was then incubated at 20°C for 60 rain, washed as described 
above, and mounted for fluorescence microscopy. As a control, total DNA 
staining was used with the dye DAPI (4,6-diamine-2 phenyl indole). 0.1 
#g/ml DAPI was added to the last wash. In these experiments DAPI- and 
FITC-labeling were never used simultaneously. 
Binding of  Monoclonal Antibodies 
500/~l of the suspended microbeads (corresponding to 250 tzl of the packed 
preparation containing 2.5  ×  106 permeabilized nuclei) were transferred to 
1.5-ml Eppendorf reaction vials (model No. 3810; Brinkman Instruments, 
Inc., Westbury, NY) using blue Eppendoff pipette tips with enlarged open- 
ings.  The  monoclonal  anti-Z-DNA  antibody  Z22  (19)  as  well  as  the 
anti-HMG-17 monoclonal antibody (5, 6) were biotinylated as prescribed 
in the Enzotin biotinylation kit (Enzo Biochem, Inc., New York). A fixed 
amount of the respective antibody was added to the microbead suspension. 
Incubation was for 2 h at room temperature, briefly vortexing the suspension 
at intervals of 20 min. To dispose of unbound antibody the vials were cen- 
trifuged at 4,800 g  at 0*C for 5 rain. The supernatant was aspirated using 
a specially mounted yellow Eppendorf pipette tip that guaranteed rapid and 
reproducible removal. The pellets were each washed three times with 1 ml 
pf isotonic buffer, allowing 20 min for sufficient diffusion of unbound anti- 
body each time, and resuspended with 500 #1 of isotonic buffer. 
Radioactive Labeling of  Antibodies 
For radioactive labeling, the Z22 antibody suspension was incubated with 
11.1 kBq of 125I-labeled streptavidin (Amersham Corp.; IM.236, 740-1480 
kBq//zg,  3.7  MBq/rnl, brought to 74-148 kBq/#g with nonlabeled strep- 
tavidin; Bethesda Research Laboratories, Gaithersburg, MD; Gibco Lab- 
oratories, Grand Island, NY). Labeling of bound HMG-17-specific mono- 
clonal antibodies was  with  11.1 kBq  1251-labeled streptavidin brought to 
7-15 kBq/~g with nonlabeled streptavidin. Cpm values were standardized 
to 74-148 kBq//zg. The incubation was the same as the fluorescence labeling 
with the exception of the final wash. The supernatant and upper parts of the 
pellet were removed by aspiration to leave exactly 100/zl. 800/~1 of Bray's 
solution were then added, the mixture was homogenized on a vortex, and 
radioactivity determined in a liquid scintillation counter by directly insert- 
ing the vial into a scintillation vial. 
Binding of  Antibodies in the Presence of Camptothecin 
Encapsulation of cells and permeabilization of nuclei were performed as de- 
scribed above. After sedimentation of microbeads,  subsequent washes in 
isotonic buffer as well as incubation with the respective antibody were in 
the presence of 60 t~M camptothecin. Camptothecin was diluted from a 20- 
mM stock solution in dimethylsulfoxide (29). The respective control experi- 
ments with no antibody added contained 0.5% (vol/vol) dimethylsulfoxide. 
Washes to remove nonbound antibody and labeling with 125I-labeled strep- 
tavidin were in the presence of 60/zM camptothecin. 
Preincubation with Polyclonal Anti-Z-DNA 
Antibodies 
A nonbiotinyla~l, polyclonal Z-DNA-speciflc antibody preparation from 
goats was used of which '°3%  (wt/wt) represent the Z-DNA specific frac- 
tion (17); the varying amounts of antibody shown in Fig. 7 were corrected 
accordingly.  Incubation with the polyclonal antibody preparation was for 
2 h at room temperature as described above for the monoclonal antibodies 
but in the presence of 60 #M camptothecin. Most of the unbound polyclonal 
antibodies were removed by washing the suspension once in isotonic buffer, 
followed by incubation with either 0.28/~g of Z-DNA-specific monoclonal 
antibody or 2.8 #g HMG-17-specific monoclonal antibody for 2 h still in 
the presence of 60 #M  camptothecin.  Labeling  with  t25I-labeled  strep- 
tadivin was also performed in the presence of 60 #M camptothecin. 
Results 
An overview of agarose microbeads containing live mouse 
myeloma cells is shown in Fig.  1 a.  The focal plane cuts 
across the sphere yielding a sharp circular boundary at the 
periphery.  The well-preserved morphology of the cells is 
demonstrated at a  higher magnification of individual cell 
groups within the beads (Fig. 1 b). In these pictures, drops 
containing the  encapsulating microbeads  were  visualized 
using Nomarski optics. The apparent three-dimensionality 
of the cells is due to differences in refractive index, and nu- 
cleoli are especially prominent. The cells maintain their po- 
sitions in the agarose gel, and cells located in the focal plane 
produce a sharp image. The cytoplasm is clearly distinguished 
from the nucleus, which shows nucleoli if the cell is situated 
The Journal of Cell Biology, Volume 108,  1989  756 Figure 1.  Microscopy of mouse myeloma cells and permeabilized nuclei encapsulated  in agarose microbeads.  (a) A single agarose bead 
containing cells  (10 ~m marker).  (b) Higher magnification  (10/~m ma/ker).  Nomarski optics is used, which is based on differences  in 
refractive  index,  and nucleoli  are especially prominent. (c) Microscopy of permeabilized nuclei encapsulated  in agarose microbe,  ads (10 
/~m marker). (d) Nuclei at higher magnification  (10/zm marker). (e) Fluorescence of isotonic encapsulated  permeabilized nuclei exposed 
to a low concentration of anti-Z-DNA antibody (0.28 #g/500 td). This was followed by addition of FITC-labeled streptavadin.  Four single 
nuclei  on the right were selected  for optically favorable conditions when they were found in the focal plane. 
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are shown in Figs.  1, c and d after the cytoplasm has been 
lysed. The nuclei are morphologically intact and nucleoli re- 
main prominent. 
To obtain information about the content and distribution 
of Z-DNA  in  the permeabilized,  microbead-encapsulated 
nuclei, they were incubated with biotinylated monoclonal 
anti-Z-DNA  antibody  (Z22).  This anti-Z-DNA  antibody 
reacts with Z-DNA irrespective of its nucleotide sequence 
(19, 21, 25), For microscopic observation a second incuba- 
tion with FITC-streptavidin was carried out to produce fluo- 
rescent-labeled antibody-Z-DNA complexes. Micrographs 
of such fluorescent nuclei are shown in Fig. 1 e. Low concen- 
trations of antibody were used, as discussed below. For pur- 
poses  of comparison,  encapsulated  permeabilized  nuclei 
were also  stained  with  DAPI,  which  labels  total  nuclear 
DNA (results not shown). Fig.  1 e shows the formation of 
Z-DNA antibody complexes in unfixed, metabolically active 
nuclei in a  native state under isotonic conditions. Isotonic 
conditions are taken as 150 mM in monovalent cations (10, 
11). The distribution of these fluorescent complexes within 
the nuclear substructure is similar to the pattern of  total DNA 
staining with DAPI. Control experiments were carried out 
under identical conditions, using a biotinylated monoclonal 
antibody against bacterial chloramphenicol acetyltransferase 
(CAT), ~ an enzyme that does not occur in myeloma cell 
nuclei. A weak, diffuse fluorescence staining was obtained 
without any substructure (results not shown). 
Binding of  Radioactively Labeled Monocional 
Antibodies to Permeabilized Nuclei 
Quantitative binding experiments were carried out by adding 
radioactive streptavidin after the Z22 monoclonal antibodies 
had been incubated with the permeabilized nuclei in the 
same isotonic medium. The rate at which antibody mole- 
cules become bound to the nucleus is shown in Fig. 2. On 
incubation with a  low concentration of anti-Z-DNA anti- 
body, an initial lag period (20-40 min)  is  seen,  possibly 
reflecting the diffusion kinetics of the antibody molecules 
into the permeabilized nuclei. By 80-120 min, maximum an- 
tibody attachment has developed. In the antibody binding ex- 
periments reported here, 120-min incubations were used un- 
less otherwise specified. Control experiments were carried 
out using a monoclonal antibody against a nonhistone chro- 
mosomal protein, high mobility group protein 17 (HMG-17) 
(5, 6). This protein is found distributed throughout the chro- 
matin and is believed to be associated with ,o5 % of the nu- 
cleosomes. HMG-17 is found at a higher concentration in ac- 
tive chromatin and at a lower level in inactive chromatin. 
Fig.  2  shows  the rate of binding  of the  HMG-17-specific 
monoclonal antibody over a 2-h time period. The binding ki- 
netics are similar to that found with the Z22 antibody, except 
that binding is somewhat faster at early times.  By 2 h the 
binding is beginning to plateau in a manner similar to that 
seen with the Z-DNA-specific monoclonal antibody. 
Fig.  3 a  shows the binding of the monoclonal antibody 
against the nonhistone chromatin protein HMG-17 as a func- 
1. Abbreviations used in this paper: CAT, bacterial chloramphenicoi acetyl- 
transferase; HMG-17, high mobility group protein 17; LIDS, lithium dodecyl 
sulfate. 
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Figure 2. Kinetics of the binding of radioactively labeled anti-Z- 
DNA or anti-HMG-17 antibody to permeabilized nuclei under iso- 
tonic conditions. 0.28 t~g of anti-Z-DNA antibody Z22 or 2.8 #g of 
anti-HMG-17 was added per 500/xl of agarose microbead suspen- 
sion. The final incubation time with the antibody was varied to obtain 
a time course for  binding. All points are the average  of  three indepen- 
dent experiments. 
tion of increasing antibody concentration. An increase in an- 
tibody binding begins to occur at 0.15/zg and it reaches a pla- 
teau of maximal binding near 0.7 #g. Thereafter there is no 
significant increase in binding even though the antibody con- 
centration increases 200-fold. HMG-17 is a chromatin pro- 
tein that has been well-characterized both in terms of its dis- 
tribution and the amounts present. Each binding experiment 
contains 2.5  x  1@ nuclei,  and it is known that each nu- 
cleus contains "~2 x  107 nucleosomes. It has been estimated 
that ,,o5%  of the nucleosomes contain HMG-17 (5); thus, 
using the measured specific activity of the antibody-strep- 
tavidin complex we can estimate that there are about twice 
as many HMG-17 molecules in the nuclei as there are HMG 
antibody molecules bound in the plateau (Fig.  3 a).  This 
control experiment suggests that the antibody is diffusing 
through the entire nucleus rather than simply penetrating 
into its peripheral segment. That there are twice as many 
HMG-17 molecules as antibody molecules may be related to 
the fact that there are two antibody combining sites per anti- 
body molecule. There is no rise in the binding of the HMG- 
17-specific monoclonal antibody at very high antibody con- 
centrations. 
Anti-Z-DNA  antibodies  influence  the  equilibrium  be- 
tween  right-handed B-DNA  and  left-handed Z-DNA  (16, 
17). Our interest is not directed toward Z-DNA that accumu- 
lates due to the presence of the anti-Z-DNA antibody but 
rather toward the presence, if any, of preexisting Z-DNA. To 
this end, we explored the effect of increasing antibody con- 
centration on the binding of anti-Z-DNA antibodies to per- 
meabilized nuclei. As above, the standard experiment used 
500 ~1 of suspended agarose beads containing 2.5  x  106 
nuclei with '~5 #g of DNA. The anti-Z-DNA antibody (Z22) 
was added to permeabilized nuclei in an isotonic medium 
with amounts ranging from 0.0056 to 280 #g. After consider- 
able washing, an excess of radioactively labeled streptavidin 
was added. Fig.  3 b shows that the binding of biotinylated 
Z22-antibody to the permeabilized nuclei is constant from 
0.28 to >28/zg, a 100-fold change in concentration. The con- 
trois in Fig. 3 b show low and constant values for either anti- 
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Figure 3. Quantitation of the binding of antibodies to permeabilized nuclei under isotonic conditions. Complex formation is measured as 
a function of antibody concentration. (a) Binding of HMG-17-specific monoclonai antibody: Permeabilized nuclei were incubated with 
varying amounts of anti-HMG-17 antibody in the same isotonic medium. Labeling was carried out as described in Fig. 2. The amount 
of complex remaining after washing is shown. All points are the average of three independent experiments. The control with no antibody 
added is the solid line. A plateau of  binding is seen but without a sharp rise at high antibody concentrations. (b) Binding of Z-DNA-specific 
monoclonal antibody: Two nonspecific background binding experiments are shown here. In one, the antibody was omitted from the reaction 
mixture (solid line). In the second, nonspecific biotinylated monoclonal anti-CAT antibody was added. Standard deviation of the mean 
values is indicated as calculated from 5 to 20 single determinations. It can be seen that the antibody to Z-DNA reaches a plateau of binding 
over a 100-fold increase in antibody concentration. More binding is seen at even higher antibody concentration. The radioactive labeling 
was as described in Materials and Methods. The suspension was incubated with 11.1 kBq of t25I-labeled streptavidin or 111 kBq in assays 
containing <2.8/~g of Z22 antibody. 
body to CAT or for the buffer alone. Because the binding of 
Z22 antibody is insensitive to antibody concentration in the 
plateau  region,  we  suggest  that  it  is  due  to  preexisting 
Z-DNA. 
At much higher concentrations of antibody the amount of 
antibody binding increases dramatically, in striking contrast 
to the binding of HMG-17-specific antibodies (Fig. 3 a). We 
know that anti-Z-DNA antibodies can perturb the B-Z equi- 
librium by trapping Z-DNA, especially at high concentra- 
tions (16, 17). Thus, it seems likely that this rise in binding 
at high antibody concentration represents the induction of 
Z-DNA specific antibody  bound 
[cpml 10000 
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Figure 4. The effect of preincubation with DNase I on the binding 
of  anti-Z-DNA antibodies to permeabiliz~ nuclei. The preincuba- 
tion was carried out at room temperature and nicking amounts of 
E. coil DNase I (0.01 U) as well as larger degrading amounts (1.0 U) 
were used. The lowest antibody concentration (2.8/~g) is from the 
concentration independent plateau region of  Fig. 3. The higher con- 
centrations are associated with antibody "induced" Z-DNA for- 
mation. 
Z-DNA either by antibody molecules directly or by displace- 
ment of Z-DNA binding proteins followed by antibody at- 
tachment. 
Torsional Strain in DNA Stabilizes Antibody-Z-DNA 
Complexes 
The DNA in these nuclei has been shown to be intact (3). 
We can ask whether the Z-DNA antibody attachment is due 
to torsional strain in the DNA. This was addressed by experi- 
ments in which the nuclei were first preincubated with low, 
nicking amounts of Escherichia  coli DNase I  (Fig. 4). 
Using an amount of antibody found in the binding plateau 
(2.8 #g as in Fig.  3 b),  preincubating with 0.01 U  DNase 
leads to a complete loss of binding within 30 rain. The anti- 
body binding at this concentration was interpreted as due to 
preexisting Z-DNA because it was independent of antibody 
concentration. This binding is entirely eliminated by small, 
nicking amounts of DNase I. 
When larger amounts of antibody are added (15 or 73 #g), 
higher initial levels of radioactive binding are observed in 
agreement with Fig. 3 b. However, preincubation with nick- 
ing amounts of DNase I removes only part of the binding of 
anti-Z-DNA antibodies.  Nicking the DNA to release tor- 
sional strain does not prevent the antibody from inducing 
Z-DNA formation (or trapping the formed Z-DNA) when 
the antibody is added later at high concentrations. However, 
preincubation with lytic amounts of DNase I (1 U) results in 
rapid loss of DNA and an inability to induce Z-DNA forma- 
tion after 60 min, even with high concentrations of antibody 
(Fig. 4). 
The experiments with nicking amounts of DNase I suggest 
that torsional strain in the DNA may be important in main- 
raining the apparently preexisting Z-DNA that is detected in 
the concentration-independent range of antibody binding in 
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Figure 5. The binding of  Z-DNA-specific and HMG-17-specific  monoclonal antibodies to encapsulated permeabilized nuclei in the presence 
of the topoisomerase I inhibitor camptothecin (60 t~M) as a function of antibody concentration. All points are the average of three indepen- 
dent experiments. The solid line is the minus antibody control. (a) The binding of Z-DNA-specific monoclonal antibody (Z22). The level 
of binding in the absence of camptothecin (Fig. 3 b) is represented by the dashed line. A plateau of binding is found in the presence of 
camptothecin but at a higher level than in Fig. 3 b. At high antibody concentrations where increased binding is seen in Fig. 3 b, a similar 
increase in binding is seen in the presence of camptothecin. (b) The binding of HMG-17 specific monoclonal antibody. 
the plateau region.  DNA torsional strain is believed to be 
maintained by the cellular DNA topoisomerases. Eukaryotic 
cells contain topoisomerases I and II, and the latter is be- 
lieved to be important in disentangling daughter DNA du- 
plexes after replication. Topoisomerase I relaxes DNA and 
it is believed to have an important role in maintaining the 
level of torsional strain. We have investigated this directly by 
using the topoisomerase I  inhibitor camptothecin (7).  Ex- 
periments  were carried out  in which  the  nuclei  were in- 
cubated with 60/zM camptothecin. Monoclonal antibodies 
were then added at varying concentrations against Z-DNA 
and against HMG-17, respectively. The results of the anti-Z- 
DNA experiments are shown in Fig.  5 a.  The dotted line 
shows the level of antibody bound in the absence of camp- 
tothecin, as presented in Fig.  3.  It can be seen that with 
camptothecin  treatment  the  plateau  is  maintained  but  at 
slightly more than a twofold increase in the level of anti-Z- 
DNA binding. As in previous experiments, very high levels 
of antibody give rise to the much larger binding that we have 
termed induced Z-DNA. In contrast, the anti-HMG-17 con- 
trol experiments in the presence of camptothecin (Fig. 5 b) 
are essentially unchanged from results without the inhibitor 
(Fig. 3 a). These findings are consistent with the results of 
experiments involving nicking amounts of DNase I. Inhibi- 
tion of topoisomerase I prevents the gradual loss of DNA tor- 
sional strain.  The higher level of torsional strain stabilizes 
more Z-DNA; this is reflected in a higher level of  bound anti- 
body but it still remains independent of antibody concentra- 
tion in the plateau region. This reinforces our interpretation 
of the plateau as a measure of preexisting Z-DNA. In con- 
trast, the binding of HMG-17-specific monoclonal antibody, 
which is simply a measure of the amount of that protein in 
the nuclei,  is unaffected by the change in DNA  torsional 
strain. 
We have carried out experiments to ask what is the effect 
of preincubation on the binding of anti-Z-DNA antibodies. 
Fig. 6 a shows the effect of preincubation at room tempera- 
ture on the subsequent binding of anti-Z-DNA antibodies. 
Three different antibody concentrations are used,  the low 
level in the plateau  region (2.8  ttg)  and higher levels as- 
sociated with induced Z-DNA formation (15 and 73  #g). 
Preincubation results in a steady decrease in the amount of 
bound antibody. The values drop slightly after 30 min prein- 
cubation and by 120 min most of the complex formation is 
lost for both the 2.8 and  15/~g additions of antibody. The 
higher value of 73/~g antibody still retains a significant com- 
ponent of the induced Z-DNA complex. 
The decay in antibody binding shown in Fig. 6 a could be 
due to the disintegration of nuclei and the release of nucleases 
or, alternatively, to the continued action of topoisomerase I 
leading to a relaxation of DNA and the loss of Z-DNA forma- 
tion.  To distinguish between these interpretations, experi- 
ments were carried out using nuclei that were incubated in 
the presence of 60 #M camptothecin to inhibit topoisomer- 
ase I. As shown in Fig. 6 b, the binding of the anti-Z-DNA 
antibody did not change as a function of time when the cells 
were incubated in the presence of the topoisomerase I inhibi- 
tor in contrast to the gradual loss of binding seen in Fig. 6 
a. To test for the breakdown of nuclei, similar experiments 
were done to measure the binding of the antibody against 
HMG-17 as a function of time (Fig. 6 b). Its binding remains 
constant over the time course of the experiment, suggesting 
that nuclei are not disintegrating.  Thus, simple preincuba- 
tion results in relaxation of DNA with time due to the action 
of topoisomerase I,  with no nuclear disintegration.  Topo- 
isomerase I inhibition leaves the anti-Z-DNA antibody bind- 
ing at a constant level in the plateau region throughout the 
2-h incubation period. 
Competition between Monoclonal and Polyclonal 
Antibodies against Z-DNA 
Polyclonal antibodies  are  available  that  have been  raised 
against poly(dG-dC) stabilized in the Z  conformation (16, 
17). The monoclonal antibody Z22 raised against the same 
antigen  was  selected  for these  experiments because  it  is 
known to bind to Z-DNA independently of nucleotide se- 
quence (19).  It has been studied extensively and footprints 
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Figure 6. The effect of preincuba- 
tion at room temperature of en- 
capsulated permeabilized  nuclei 
on the binding of the monoclonal 
antibodies. All points are the av- 
erage  of three  independent  ex- 
periments.  (a)  The  binding  of 
anti-Z-DNA  antibody (Z-22) at 
three  different  concentrations. 
The lowest concentration is in the 
plateau region. It can be seen that 
there is a steady drop with time, 
although the binding finally is sta- 
bilized  at  the  highest  antibody 
concentration. (b) The effect  of  the 
topoisomerase I inhibitor camptothecin (60 #M) on the binding of anti-Z-DNA antibody Z22 (0.28/.tg) and anti-HMG-17 (2.8 #g). The 
binding is independent of time for this preincubation period for both antibodies. 
have been obtained of it against Z-DNA (25). The epitope 
for  its  binding  is  probably  found in  the  sugar-phosphate 
backbone of  the Z-DNA conformation. In contrast, the poly- 
clonal antibodies are known to contain antibodies directed 
against a large number of epitopes. Some immunogenic epi- 
topes  may be  associated  with  the  purine  and  pyrimidine 
rings. It could be argued that the binding of the monoclonal 
antibody Z22  is nonspecific, despite its sensitivity to tor- 
sional strain. If it were specific, there should be competition 
between it and the nonbiotinylated polyclonal antibody. In 
such a  competition experiment, longer incubation periods 
are used. To prevent the loss of the Z-DNA due to continued 
topoisomerase activity as in Fig. 6 a, the nuclei were main- 
tained in 60 #M camptothecin to inhibit topoisomerase I. 
The nuclei were first incubated for 2 h with varying amounts 
of IgG fractions containing unlabeled polyclonal antibody 
against Z-DNA. After this the nonbiotinylated antibody was 
washed out and the nuclei were then incubated for 2 h with 
0.28/xg of labeled Z22 monoclonal antibody. Fig. 7 shows 
the binding of the monoclonal antibody as a function of in- 
creasing concentration of polyclonal antibody. Little effect is 
seen up to a concentration of "o0.3 #g of added polyclonal 
antibody. At higher concentrations, there is a gradual loss of 
the binding of the labeled monoclonal antibody. There is 
competition between the binding of unlabeled polyclonal an- 
tibody and the labeled monoclonal antibody. Included in Fig. 
7 are also control experiments in which the binding of  mono- 
clonal antibodies against the chromatin protein HMG-17 was 
measured. This binding is unaffected by the addition of in- 
creasing amounts of polyclonal antibody against Z-DNA. 
The Effect of Deproteinization  and 
Cytological Fixation 
It is known that changes in solvent conditions can cause con- 
formational changes in chromatin, and these changes may be 
crucial for the transition between B- and Z-DNA. We have 
investigated the effect of varying the treatment of the encap- 
sulated nuclei on anti-Z-DNA antibody binding.  Fig.  8 a 
shows experiments in which binding was measured after the 
nuclei had been exposed to different salt concentrations dur- 
ing permeabilization. A "noninducing" antibody concentra- 
tion was used in these experiments. Only slight changes are 
observed on  varying  salt  from 0.025  to  0.17  molarity  of 
monovalent cations. In the experiments shown in Fig. 8, con- 
trois were also carried out by adding biotinylated anti-CAT 
antibodies  followed by  radioactively labeled  streptavidin. 
Those results (not shown) were 10-15 % greater than the "no 
antibody" control that is plotted in the figure. Anti-Z-DNA 
antibody binding is not very sensitive to changes in this range 
of salt concentration. The effect of treating cells with higher 
concentrations of salt will be presented elsewhere. 
What is the effect of protein removal? Lithium dodecyl sul- 
fate (LIDS) treatment is  known to remove most proteins. 
Cook (3) has shown that this treatment yields DNA that is 
unbroken, and it has maximum negative supercoiling, which 
would stabilize Z-DNA. Under this treatment, fourfold in- 
crease of complex formation with the anti-Z-DNA antibody 
is observed (Fig. 8 b). Z-DNA has been frequently studied 
in tissues by fixation, followed by addition of anti-Z-DNA 
antibodies for fluorescence staining (15, 20, 22). The effect 
of two such treatments is shown quantitatively in Fig.  8 b. 
These lead to an approximately threefold elevated signal com- 
pared to the preexisting Z-DNA found in the isotonic per- 
meabilization. The level of the signal is not as high as with 
LIDS, presumably because the fixation treatment strips away 
only part of the proteins from the chromosomal DNA (2, 4). 
Discussion 
Much work has been carried out in an attempt to measure 
Z-DNA  content of nuclei  using  anti-Z-DNA  antibodies. 
These experiments all have to be analyzed in the light of two 
significant artifacts that can perturb the measurement. The 
first is the state of the chromatin in the nucleus. To what ex- 
tent is it close to in vivo or have experimental conditions 
significantly altered the chromatin? The second question is 
the extent to which the use of anti-Z-DNA antibody binding 
to the DNA significantly disturbs the B-DNA/Z-DNA equi- 
librium? In the experiments described above we have consid- 
ered both of these issues. 
The quality of the encapsulated permeabilized physiologi- 
cal active nuclei has been addressed by using the novel ap- 
proach of Jackson and Cook. They have shown that HeLa 
cells trapped in agarose beads as well as their permeabilized 
nuclei are morphologically intact (9).  The myeloma cells 
used in these experiments are also intact and the permeabi- 
lized nuclei prepared after treatment with 0.5 % Triton X-100 
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Figure 7. Effect of adding polyclonal anti-Z-DNA antibodies on the 
binding  of monoclonal antibodies  against Z-DNA and  HMG-17 
nonhistone  chromatin  proteins.  The encapsulated  permeabilized 
nuclei were first incubated with unlabeled polyclonal anti-Z-DNA 
antibodies at varying concentrations. Subsequently,  the binding of 
monoclonal  antibodies  against  Z-DNA  and  HMG-17  was  mea- 
sured. All points are the average of three independent experiments. 
The binding of anti-HMG-17 is not affected by the preincubation. 
However, competitive binding  is seen for the anti-Z-DNA anti- 
bodies. 
in an isotonic buffer look similar to those in the intact cell 
(Fig.  1).  The nuclei are transcriptionally  active (11) and  in 
quantitative experiments Jackson and Cook have shown that 
the rate of DNA synthesis in these nuclei is 85 % of the rate 
in vivo (12). In these preparations the DNA has been shown 
to be unbroken and under torsional strain (3, 9,  10,  11). The 
buffer medium is isoltonic but it should be noted that it con- 
tains 1 mM EDTA and no divalent cations to keep nucleases 
inactive. This is the only preparative method that allows the 
DNA of chromatin  to remain intact so it can be studied  in 
an isotonic salt solution.  Individual nuclei generally aggre- 
gate under  these  conditions,  but the agarose matrix  keeps 
them separate.  These permeabilized nuclei are good prepa- 
rations for accessing DNA torsional strain and measuring the 
Z-DNA content,  since they are metabolically active. 
The control experiments using anti-HMG-17 antibody ad- 
dress the question of how well antibodies measure the con- 
tent of nuclear components. On increasing the antibody con- 
centration,  a  binding  plateau  is  found  near  one  antibody 
molecule per two HMG-17 molecules (Fig. 3 a). This could 
be due to the fact that only half of them are accessible; alter- 
natively,  each  antibody  binding  site may find an  HMG-17. 
Further, this binding plateau does not change in other experi- 
ments in which  torsional  strain  in DNA is altered. 
It has been shown that anti-Z-DNA antibodies can induce 
Z-DNA  formation,  especially  if the  antibodies  bind  with 
high affinity (16,  17).  The monoclonal antibody used in this 
experiment is not a high affinity antibody but it has the prop- 
erty of recognizing  Z-DNA  independent  of nucleotide  se- 
quence (19, 21).  A "footprint" has revealed how the antibody 
binds to Z-DNA (25).  The binding of anti-Z-DNA antibod- 
ies to the permeabilized nuclei  is a  multiphasic  process as 
a function of antibody concentration:  no binding is found at 
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Figure 8. The influence of deproteinization and fixation conditions 
on complex formation at a noninducing antibody concentration (2.8 
ttg).  (a) Dependence on the concentration of monovalent cations 
below and near the isotonic range. The cation concentrations indi- 
cated on the horizontal axis were used during the permeabilization 
treatment. (b) The effect of LiDS (cell lysis in 1% [wt/vol]  LIDS, 
100 mM EDTA, 10 mM Tris-HC1, pH 8.0, see Cook [reference 3]). 
Two different cytological fixation conditions are also shown. These 
were carried out on encapsulated permeabilized nuclei. (Fix 1:45 % 
acetic acid, 10 min; fix 2: ethanol/acetic acid 3:1, 10 min, followed 
by 45% acetic acid,  10 min [15, 22].) 2.8 #g of Z22 antibody were 
used per assay. The standard deviations of the mean refer to six de- 
terminations  each.  In these experiments,  an anti-CAT antibody 
control was also carried out. The results (not shown) were 10-15 % 
higher than the minus antibody control. 
very low concentrations but once a threshold concentration 
is reached, the binding remains constant.  The amount of ra- 
dioactive antibody bound to the nuclei remains constant over 
a  100-fold change in antibody concentration (Fig. 3 b). Only 
upon going to much higher antibody concentrations does the 
amount of bound antibody increase. This is probably due to 
the antibody trapping Z-DNA in the B-Z equilibrium as im- 
plied  in  calling  it  induced  Z-DNA.  Addition  of nicking 
amounts of DNase I cause a rapid loss in the binding of anti- 
body present at a  concentration  in the plateau range.  How- 
ever,  the induced  Z-DNA-antibody  complex is not greatly 
affected by DNA nicking.  Likewise, inhibition of topoisom- 
erase I leads to a higher plateau level of Z-DNA binding. We 
have interpreted these experiments as providing a  basis for 
separating  the  Z-DNA found  into preexisting  and  induced 
components.  The lower antibody concentrations  in the pla- 
teau  region  measure  the  preexisting  component.  That  is 
taken as a measure of the amount of Z-DNA found in the nu- 
cleus under conditions  in which the DNA is unbroken,  the 
salt solution is isotonic, and the nucleus is active in both tran- 
scription and replication. 
Is it likely that the plateau binding of anti-Z-DNA antibod- 
ies (Fig. 3 b) is not due to preexisting Z-DNA? For example, 
could a low concentration of the antibody "trigger" the induc- 
tion of Z-DNA to produce the plateau? There are many rea- 
sons that such an interpretation is improbable. The constancy 
of binding over a  100-fold increase in concentration is most 
simply interpreted as preexisting Z-DNA. The variability of 
the plateau binding level in response to changes in DNA tor- 
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entirely with DNA nicking) is fully interpretable in terms of 
our current understanding of the behavior and stabilization 
of Z-DNA. 
In addition to trapping  Z-DNA in the B-Z equilibrium, 
other mechanisms can be considered in the production of in- 
duced Z-DNA associated with high concentrations of anti- 
body. Z-DNA binding proteins may be displaced by the anti- 
body. Alternatively, chromosomal or nucleosomal proteins 
may be displaced leading to regions of unrestrained torsional 
stress in the nuclear DNA. Finally, there may be direct in- 
duction of the Z  conformation in protein-free stretches of 
DNA by cooperative binding of antibody molecules. To get 
a correct assessment of preexisting Z-DNA, it is important 
to use conditions that prevent all of these from occurring. 
The experiments shown in Fig. 8 b reveal the extent of fixa- 
tion artifacts. Removal of virtually all chromosomal proteins 
by LiDS without nicking the DNA results in a fourfold in- 
crease in the binding of anti-Z-DNA antibodies even at the 
low concentration of antibodies found in the plateau region. 
This Z-DNA stabilization is undoubtedly due to the release 
of negative supercoiling in the DNA even in the presence of 
noninducing antibody concentrations. Classical fixation pro- 
cedures produce approximately a threefold increase in anti- 
body binding.  Proteins are removed by fixation, but not as 
many as with the LiDS treatment. It is likely that even higher 
levels of antibody binding would be found if concentrations 
of antibody were used that induced Z-DNA formation. 
Our conclusions are different from those of Hill and Stol- 
lar who failed to observe antibody binding in microdissected 
Drosophila polytene chromosomes (8). The different results 
could be due to two effects. First, the microdissected chro- 
mosome is put into a buffer environment that is quite differ- 
ent from that of the intact nucleus which could lead to a loss 
of Z-DNA. In addition, it is likely that during the microdis- 
section and  further processing of polytene chromosomes, 
endogeneous topoisomerases were active and resulted in a 
loss of  preexisting Z-DNA as we have observed during prein- 
cubation (Fig. 4 b). Hill and Stollar found that it required a 
removal of chromosomal proteins by a  fixation process to 
produce antibody binding. Recent work by Lancillotti et al. 
have demonstrated  binding  of anti-Z-DNA  antibodies  to 
unfixed Drosophila  polytene chromosomes (18). The differ- 
ence between their results and Hill and Stollar's suggests that 
specific manipulations used in isolating individual polytene 
chromosomes may result in the loss of Z-DNA. 
The DNA in the nucleus is likely to be in a dynamic state, 
with some processes generating negative torsional strain and 
other processes reducing the strain. Topoisomerase I reduces 
negative torsional strain. We have made two measurements 
of Z-DNA antibody binding in the noninducing plateau re- 
gion. One measurement after 120 min of incubation without 
camptothecin (Fig.  3  b)  and a  second in the presence of 
camptothecin (Fig. 5 a). Based on the experiments described 
in this article, we conclude that a level of preexisting Z-DNA 
is found in the myeloma nucleus when it is measured under 
conditions in which there is no induced Z-DNA formation. 
Using  the  quantitative  data  presented  above,  the  known 
specific activity of streptavidin and the fact that there is one 
biotinylation site per antibody, we find one antibody mole- 
cule is bound per 100 kbp of DNA in the absence of camp- 
tothecin and one antibody per 50 kbp when topoisomerase 
I is inhibited. If we assume that topologically isolated do- 
mains of chromatin contain '~100 kb (~500 nucleosomes), 
we estimate that there is on the average about one or two 
preexisting Z-DNA binding sites for an antibody molecule 
per domain, or one or two per 500 nucleosomes. However, 
there is no reason to believe that these sites are randomly dis- 
tributed,  and they may in  fact be concentrated in  certain 
regions. 
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